CADL vs LYEL
CADL: Clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies to trigger systemic anti-tumor immune responses by inducing immunogenic cell death within solid tumors. LYEL: Late-stage clinical cell therapy company engineering next-generation dual-targeting CD19/CD20 CAR T-cell therapies for blood cancers and solid tumors, with a lead program in pivotal trials and an in-house manufacturing facility.
Side-by-side fundamentals
| Metric | CADL | LYEL | Edge |
|---|---|---|---|
| Price as of 2026-08-11 close | $10.65 | $14.88 | |
| Market cap as of 2026-08-12 | $780M | $365M | |
| Net margin as of 2026-08-12 | -15156.5% | -794858.1% | CADL higher |
| Operating margin as of 2026-08-12 | -28000.8% | -823341.9% | CADL higher |
| ROE as of 2026-08-12 | -60.4% | -85.7% | CADL higher |
| ROA as of 2026-08-12 | -41.3% | -66.4% | CADL higher |
| Debt / equity as of 2026-08-12 | 0.34 | 0.00 | LYEL lower |
| Revenue growth (YoY) as of 2026-08-12 | n/a | -52.3% | |
| Revenue CAGR (3y) SEC XBRL | +0.0% | -92.5% | CADL higher |
| Beta as of 2026-08-12 | -0.33 | -0.04 | |
| 1-year return as of 2026-08-11 close | +71.5% | +40.6% | CADL higher |
Fundamentals: market data, as of 2026-08-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-11.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.